Proteinuria Treatment Market Size, Share, and COVID-19 Impact Analysis By Drug Class (ACE Inhibitors, Angiotensin II Receptor Antagonists (ARBs), Diuretics, and Others), By Type (Transient, Orthostatic, Persistent, and Others), By Distribution Channel (Hospital Pharmacies, Retail, and Online Pharmacies), and Regional Forecast, 2025-2032

Sedentary lifestyles accompanied by the lack of exercise, inadequate diet, increase in consumption of alcohol, and avoidance of routine health checkup has led to an increase in the prevalence of chronic diseases such as diabetes, and cardiovascular diseases. These conditions further lead to co-morbid conditions where there is a higher chance of kidney disease or nephrotic syndrome, causing the protein to stay in the urine for extended periods. Along with this, high intensity of physical activity, dehydrated body, high stress, and fever are also responsible for increased protein levels in urine.

• For instance, according to an article published in Kidney Disease Improving Global Outcomes (KDIGO) in October 2022, approximately 40.0% or more of people with diabetes are likely to develop chronic kidney disease (CKD).
• Also, according to the statistics published by Chronic Kidney Disease in 2021, 39.0% of end-stage renal diseases in the U.S. were caused due to diabetes, and 26.0% of cases were caused due to high blood pressure.

As a part of treatment, healthcare personnel are emphasizing treating proteinuria symptoms from their origin, which includes medication and changes in daily lifestyle. Therefore, the rising cases of chronic kidney disease and patients with proteinuria have contributed to increased utilization of ACE inhibitors and Angiotensin II Receptor Antagonists (ARBs) medications.

• For instance, according to an article published by MDinteractive in January 2023, 37.0 million Americans are suffering from chronic kidney disease (CKD).
• To control this, population health is focusing on increasing the use of ACE inhibitors and Angiotensin II Receptor Antagonists (ARBs) among the American Indians and Alaska Natives population to decrease the rate of kidney failure and mortality rate in patients with chronic kidney disease and proteinuria, the same article stated.

The rising prevalence of proteinuria and the increasing demand for medications for treatment has encouraged numerous companies to focus on research and development of new medications and introduce these products to the market.

• For instance, in December 2021,  Tarpeyo (budesonide), a delayed-release capsule received accelerated approval from the U.S. FDA. The capsules aid in reducing proteinuria in adult patients with primary immunoglobulin A (IgA) nephropathy.

Impact of COVID-19 on the Proteinuria Treatment Market

The emergence of COVID-19 has resulted in considerable growth for proteinuria treatment medications, as the consumption of ACE inhibitors and Angiotensin II Receptor Antagonists (ARBs) surged during COVID-19. Their ability to decrease the mortality risk and moderate the hyperinflammatory response were the reasons for the surge in demand for the products, according to an article published by Health Data Science in December 2022.

Moreover, according to a study conducted by UnitedHealth group in May 2020, medicare advantage (MA) members who were prescribed ACE inhibitors saw their risk of hospitalization reduced by nearly 40.0% during the COVID-19 pandemic.

Key Insights

The report will cover the following key insights:

• New Product Launches, By Key Players.
• Recent Industry Developments Such as Mergers & Acquisitions.
• Pipeline Analysis, Key Players.
• Impact of COVID-19 on the Market.

Analysis by Mode of Action

The lack of daily exercise, with increasing adoption of unhealthy lifestyles, has led to the rising prevalence of chronic diseases such as diabetes and blood pressure. This rising prevalence of chronic diseases has contributed to increased demand for medications such as ACE inhibitors and angiotensin II receptor antagonists (ARBs), contributing to the segment's growth.

• For instance, according to the statistics published by European Parliamentary Research Service (EPRS) in November 2022, approximately 537.0 million people aged between 20 to 79 across the world were living with diabetes in 2021, which is expected to rise to 783.0 million by 2045.

In addition, clinical conditions such as certain immune disorders such as lupus, goodpasteur syndrome, acute kidney inflammation, intravascular hemolysis, and simultaneous development of preeclampsia in pregnant women are a few of the diseases contributing to the increase in the demand for the products and surging segmental growth.

Regional Analysis

To gain extensive insights into the market, Download for Customization

The rising prevalence of glomerular disease and other chronic conditions, such as cardiovascular disease, has increased the demand for proteinuria treatment products. This rising demand has led to intense competition among manufacturers, which has emphasized companies' focus on the research and development of medication and introduced it as a new treatment option, contributing to the market's growth across regions.

• For instance, in March 2022, Eli Lilly and Company received a positive efficacy rate in the EMPA-KIDNEY trial to evaluate Jardiance in adults with chronic kidney disease. The trial included patients with normal and increased albumin levels, a type of proteinuria, and patients with reduced estimated glomerular filtration rate (eGFR).

Key Players Covered

The report will include the profiles of key players such as AstraZeneca, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited., Sanofi, Travere Therapeutics, Inc., Calliditas Therapeutics AB, Novartis AG, and others.

Segmentation

Key Industry Developments

The emphasis of key manufacturers on receiving approval from regulatory authorities for the treatment of proteinuria is contributing to the market's growth.

• February 2023: Travere Therapeutics, Inc., received accelerated approval from U.S. FDA for FILSPARI, an oral medication which aids in the reduction of proteinuria in adults with primary Immunoglobulin A Nephropathy (IgAN).
• June 2022: Alnylam Pharmaceuticals, Inc., declared results from a phase 2 study of cemdisiran, an investigational RNAi therapeutic that targets C5 component of the complement pathway. The study demonstrated reductions in proteinuria, an essential factor of Immunoglobulin A (IgA) nephropathy.